Lifitegrast Patent Expiration
Lifitegrast is Used for relieving symptoms of dry eye disease. It was first introduced by Bausch And Lomb Inc
Lifitegrast Patents
Given below is the list of patents protecting Lifitegrast, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xiidra | US11058677 | LFA-1 inhibitor formulations | Dec 18, 2033 | Bausch And Lomb Inc |
| Xiidra | US9085553 | LFA-1 inhibitor and methods of preparation and polymorph thereof | Jul 25, 2033 | Bausch And Lomb Inc |
| Xiidra | US8927574 | Crystalline pharmaceutical and methods of preparation and use thereof | Nov 12, 2030 | Bausch And Lomb Inc |
| Xiidra | US9353088 | Crystalline pharmaceutical and methods of preparation and use thereof | Oct 21, 2030 | Bausch And Lomb Inc |
| Xiidra | US9890141 | Crystalline pharmaceutical and methods of preparation and use thereof | Oct 21, 2030 | Bausch And Lomb Inc |
| Xiidra | US8168655 | Compositions and methods for treatment of eye disorders | May 09, 2029 | Bausch And Lomb Inc |
| Xiidra | US8367701 | Crystalline pharmaceutical and methods of preparation and use thereof | Apr 15, 2029 | Bausch And Lomb Inc |
| Xiidra | US9447077 | Crystalline pharmaceutical and methods of preparation and use thereof | Apr 15, 2029 | Bausch And Lomb Inc |
| Xiidra | US8084047 | Compositions and methods for treatment of eye disorders | May 17, 2026 | Bausch And Lomb Inc |
| Xiidra | US8592450 | Compositions and methods for treatment of eye disorders | May 17, 2026 | Bausch And Lomb Inc |
| Xiidra | US7314938 | Modulators of cellular adhesion |
Mar 10, 2025
(Expired) | Bausch And Lomb Inc |
| Xiidra | US10124000 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
| Xiidra | US7745460 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
| Xiidra | US7790743 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
| Xiidra | US7928122 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
| Xiidra | US9216174 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Lifitegrast's patents.
Latest Legal Activities on Lifitegrast's Patents
Given below is the list recent legal activities going on the following patents of Lifitegrast.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Withdrawal of Application for PTE Critical
| 02 Jul, 2024 | US8084047 |
| Withdrawal of Application for PTE Critical
| 02 Jul, 2024 | US8168655 |
| Withdrawal of Application for PTE Critical
| 02 Jul, 2024 | US8592450 |
| Notice of Final Determination -Eligible | 02 Jul, 2024 | US7314938 |
| Withdrawal of Application for PTE Critical
| 02 Jul, 2024 | US7790743 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2024 | US9447077 |
| Paralegal TD Not accepted | 14 Feb, 2024 | US7314938 |
| Email Notification Critical
| 17 Jan, 2024 | US7314938 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 17 Jan, 2024 | US7314938 |
| Email Notification Critical
| 05 Jan, 2024 | US8592450 |
Lifitegrast's Family Patents
